Drugs / GSK2618960
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02293161 | Nov 2014 → Sep 2015 | autoimmune disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01808482 | Mar → Aug 2013 | relapsing-remitting multiple sclerosis | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03239600 | Sep → Oct 2017 | autoimmune disease | GlaxoSmithKline | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-12-06 | GlaxoSmithKline | Results Update regarding 2010 Nature Medicine study gsk.com ↗
An early clinical study in which healthy volunteers were receiving an investigational drug targeting the same signaling pathway** was also stopped in June as a precautionary measure. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-12-06 | GlaxoSmithKline | Update regarding 2010 Nature Medicine study gsk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2618960 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02293161 ↗ |
| Action | Inhibit | “GSK2618960 was well tolerated and blocked IL-7 receptor signalling upon full target engagement.” PMID 30161291 ↗ Dec 2018 |
| Modality | Monoclonal antibody | “GSK2618960 is a humanized Immunoglobulin G 1 ( IgG1) monoclonal antibody (mAb)” NCT02293161 ↗ |
| Route | Intravenous | “GSK2618960 solution for IV Infusion up to 1 hr” NCT01808482 ↗ |